



PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/646,948
	Filing Date	August 21, 2003
	First Named Inventor	Krisztina M. ZSEBO
	Art Unit	Not Yet Assigned
	Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	10 + 36 Refs.	Attorney Docket Number 220002064500

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (3 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Form PTO-1449 (3 pages in duplicate) 2. References (36) 3. Return receipt postcard
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	MORRISON & FOERSTER LLP Shantanu Basu - 43,318	(Customer No. 25226)
Signature		
Date	March 16, 2004	

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: March 16, 2004Signature: Martina Placid

(Martina Placid)



PATENT
Docket No. 220002064500

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on March 16, 2004.

Martina Placid

Martina Placid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Krisztina M. ZSEBO et al.

Serial No.: 10/646,948

Filing Date: August 21, 2003

For: METHOD OF GENERATING AN
IMMUNE RESPONSE AND
COMPOSITIONS USED FOR SAME

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Pursuant to the USPTO notice dated July 11, 2003, waiving the requirement under 37 C.F.R. § 1.98 (a)(2)(i) to provide copies of U.S. Patents and U.S. Published Applications, copies of those references are

not submitted. Copies of foreign documents and non-patent literature are submitted herewith.
The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of ___ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of ___ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.


The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does

not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 220002064500. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: March 16, 2004

Respectfully submitted,

By: 
Shantanu Basu
Registration No. 43,318

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5995
Facsimile: (650) 494-0792

Form PTO-1449

Docket Number 220002064500

Application Number 10/646,948

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Krisztina M. ZSEBO et al.

Filing Date August 21, 2003

Group Art Unit Not Yet Assigned

Mailing Date March 16, 2004

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	04/05/1977	4,016,253	Switzer et al.			
	2.	03/13/1984	4,436,728	Ribi et al.			
	3.	02/23/1988	4,726,947	Shimada et al.			
	4.	10/15/1991	5,057,540	Kensil et al.			
	5.	12/31/1991	5,077,284	Loria et al.			
	6.	12/15/1992	5,171,568	Burke et al.			
	7.	04/18/1995	5,407,684	Loria et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	8.	11/17/1991	WO 91/16924	WIPO			
	9.	10/01/1992	WO 92/16231	WIPO			
	10.	08/10/2000	WO 00/45840	WIPO			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	11.	Anderson, P. et al. (1977). "Immunogenicity in Weanling Rabbits of a Polyribophosphate Complex from <i>Haemophilus influenzae</i> Type b," <i>J. Inf. Dis.</i> 136(S):S63-S70.
	12.	Azougagh-Oualane, F. et al. (1992). "Effects of Aprotinin on Heparin Activities and Heparin Neutralization with Protamine," <i>Thromb. Res.</i> 68(2):185-193.
	13.	Bizzini, B. (1984). "Tetanus" Chapter 2 In <u>Bacterial Vaccines</u> Germanier, R. ed., Academic Press, Inc.: Orlando, FL. pp. 37-68.
	14.	Brown, H.M. et al. (1959). "Chronic Bronchitis in Industry," <i>Br. Med. J.</i> 1:263-267.
	15.	Cole, T.-C. et al. (1989). "Isolation and Characterisation of a Neutral Proteinase From the Canine Intervertebral Disc," <i>Biochim. Biophys. Acta.</i> 990:254-262.
	16.	DiPetrillo, M.D. et al. (2000). "Safety and Immunogenicity of <i>phoP/phoQ</i> -deleted <i>Salmonella typhi</i> expressing <i>Helicobacter pylori</i> Urease in Adult Volunteers," <i>Vaccine</i> 18:449-459.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 220002064500	Application Number 10/646,948
	Applicant Krisztina M. ZSEBO et al.	
	Filing Date August 21, 2003	Group Art Unit Not Yet Assigned
	Mailing Date March 16, 2004	

17.	Eisenstein, T.K. et al. (1998). "Immunosuppression and Nitric Oxide Production Induced by Parenteral Live Salmonella Vaccines Do Not Correlate with Protective Capacity: a <i>phoP</i> ::Tn10 Mutant Does Not Suppress But Does Protect," <i>Vaccine</i> 16(1):24-32.
18.	Eisenstein, T.K. (1999). "Mucosal Immune Defense: The <i>Salmonella typhimurium</i> Model" Chapter 3 <i>In Intracellular Bacterial Vaccine Vectors</i> , Paterson, Y. ed. Wiley-Liss, Inc. pp. 51-109.
19.	Fine, P.E.M. et al. (1987). "Reflections on the Efficacy of Pertussis Vaccines," <i>Rev. Infect. Dis.</i> 9(5):866-883.
20.	Gentschev, I. et al. (2002). "The <i>E. coli</i> α -hemolysin Secretion System and Its Use in Vaccine Development," <i>Trends in Microbiology</i> 10(1):39-45.
21.	Ghosh, D. et al. (2002). "Paneth Cell Trypsin is the Processing Enzyme for Human Defensin-5," <i>Nature Immunology</i> 3(6):583-590.
22.	Hone, D.M. et al. (1999). "Mucosal Vaccination with <i>Salmonella</i> Vaccine Vectors" Chapter 6 <i>In Intracellular Bacterial Vaccine Vectors</i> , Paterson, Y. ed. Wiley-Liss, Inc. pp. 171-221.
23.	Hornick, R.B. et al. (1970). "Typhoid Fever: Pathogenesis and Immunologic Control," <i>N. Eng. J. Med.</i> 283(13):686-691.
24.	Laura, R. et al. (1980). "(<i>p</i> -Amidinophenyl)methanesulfonyl Fluoride, an Irreversible Inhibitor of Serine Proteases," <i>Biochemistry</i> 19:4859-4864.
25.	Linhardt, R.J. et al. (1995). "Dermatan Sulfate as a Potential Therapeutic Agent," <i>Gen. Pharmacol.</i> 26(3):443-451.
26.	Mäkelä, P.H. et al. (1977). "Polysaccharide Vaccines of Group A <i>Neisseria meningitidis</i> and <i>Haemophilus influenzae</i> Type b: A Field Trial in Finland," <i>J. Inf. Dis.</i> 136(S):S43-S50.
27.	Manclark, C.R. et al. (1984). "Pertussis" Chapter 3 <i>In Bacterial Vaccines</i> Germanier, R. ed., Academic Press: Orlando, FL. pp. 69-106.
28.	Panyutich, A. et al. (1991). "Activated α_2 -Macroglobulin Is a Principal Defensin-Binding Protein," <i>Am. J. Respir. Cell Mol. Biol.</i> 5:101-106.
29.	Panyutich, A.V. et al. (1995). "Human Neutrophil Defensin and Serpins Form Complexes and Inactivate Each Other," <i>Am. J. Respir. Cell Mol. Biol.</i> 12:351-357.
30.	Pappenheimer, A. M. (1984). "Diphtheria" Chapter 1 <i>In Bacterial Vaccines</i> Germanier, R. ed., Academic Press: Orlando, FL. pp. 1-36.
31.	Parke, J.C. et al. (1977). "Interim Report of a Controlled Field Trial of Immunization with Capsular Polysaccharides of <i>Haemophilus influenzae</i> Type b and Group C <i>Neisseria meningitidis</i> in Mecklenburg County, North Carolina (March 1974-March 1976)," <i>J. Inf. Dis.</i> 136(S):S51-S56.
32.	Pltokin, S.A. et al. eds. (1999). <i>Vaccines</i> Third Edition WB Saunders Co.: Philadelphia, PA pp xvii-xix (Table of Contents Only.)

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 220002064500	Application Number 10/646,948
	Applicant Krisztina M. ZSEBO et al.	
	Filing Date August 21, 2003	Group Art Unit Not Yet Assigned
	Mailing Date March 16, 2004	

33.	Schmidtchen, A. et al. (2001). "Dermatan Sulphate is Released by Proteinases of Common Pathogenic Bacteria and Inactivates Antibacterial α -defensin," <i>Mol. Microbiol.</i> 39(3):708-713.
34.	Shata, M.T. et al. (2000). "Recent Advances with Recombinant Bacterial Vaccine Vectors," <i>Molecular Medicine Today</i> 6:66-71.
35.	Sirard, J-C. et al. (1999). "Live Attenuated <i>Salmonella</i> : A Paradigm of Mucosal Vaccines," <i>Immun. Rev.</i> 171:5-26.
36.	Sweadner, K.J. (1991). "Trypsin Inhibitor Paradoxically Stabilizes Trypsin Activity in Sodium Dodecyl Sulfate, Facilitating Proteolytic Fingerprinting," <i>Anal. Biochem.</i> 194(1):130-135.
37.	Takahashi, H. et al. (1990). "Induction of CD8+ Cytotoxic T Cells by Immunization with Purified HIV-1 Envelope Protein in ISCOMs," <i>Nature</i> 344:873-875.
38.	Tzschaschel, B.D. et al. (1996). "An <i>Escherichia coli</i> Hemolysin Transport System-Based Vector for the Export of Polypeptides: Export of Shiga-like Toxin IIeB Subunit by <i>Salmonella typhimurium aroA</i> ," <i>Nat. Biotechnology</i> 14:765-769.
39.	Uchino, T. et al. (1993). "Isolation and Characterization of a Novel Serine Proteinase Complexed with α_2 -Macroglobulin From Porcine Gastric Mucosa," <i>J. Biol. Chem.</i> 268(1):527-533.
40.	Valore, E.V. et al. (1996). "Intramolecular Inhibition of Human Defensin HNP-1 by Its Propiece," <i>J. Clin. Invest.</i> 97(7):1624-1629.
41.	Wilson, C.L. et al. (1999). "Regulation of Intestinal α -Defensin Activation by the Metalloproteinase Matrilysin in Innate Host Defense," <i>Science</i> 286:113-117.
42.	Xiang, R. et al. (2001). "Protective Immunity Against Human Carcinoembryonic Antigen (CEA) Induced by an Oral DNA Vaccine in CEA-Transgenic Mice," <i>Clinical Cancer Research</i> 7:856S-864S.
43.	Zasloff, M. (2002). "Trypsin, for the defense," <i>Nature Immunology</i> 3(6):508-510.

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.